
Dr Escobar on CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer
“What we have to rely on [regarding treatment decision-making with CDK4/6 inhibitors] is evaluating retrospective analyses of real-world data and real-world effectiveness [for patients with HR-positive metastatic breast cancer].” Mauricio Escobar, MD, …